ConductScience.org, home

85,013 comparisons from ClinicalTrials.gov.

85,013 comparisons

Most participants first33,758 with no events in either group come last2,941 to 2,960 of 85,013

Show the results as
ComparisonWith the outcomeRisk difference, 95% intervalParticipantsTrial
Absorb BVS vs XIENCE: Number of Participants With Target Vessel Revascularization (TVR)44 of 1,236

39 of 1,255

0.5 points

-1.0 to 1.9

2,491NCT02173379

Absorb IV Randomized Controlled Trial

Absorb BVS vs XIENCE: Number of Participants Experienced All Death/All MI116 of 1,236

106 of 1,255

0.9 points

-1.3 to 3.2

2,491NCT02173379

Absorb IV Randomized Controlled Trial

Absorb BVS vs XIENCE: Number of Participants Experienced Cardiac Death/All MI107 of 1,236

96 of 1,255

1.0 points

-1.1 to 3.2

2,491NCT02173379

Absorb IV Randomized Controlled Trial

Absorb BVS vs XIENCE: Number of Participants Experienced Death/All MI/All Revascularization (DMR)185 of 1,236

161 of 1,255

2.1 points

-0.6 to 4.9

2,491NCT02173379

Absorb IV Randomized Controlled Trial

Absorb BVS vs XIENCE: Number of Death (Cardiac, Vascular, Non-cardiovascular)22 of 1,236

22 of 1,255

0.0 points

-1.0 to 1.1

2,491NCT02173379

Absorb IV Randomized Controlled Trial

Absorb BVS vs XIENCE: Number of Participants With Myocardial Infarction (MI)104 of 1,236

86 of 1,255

1.6 points

-0.5 to 3.7

2,491NCT02173379

Absorb IV Randomized Controlled Trial

Absorb BVS vs XIENCE: Number of Participants Experienced Cardiac Death/All MI/ID-TLR (MACE)146 of 1,236

121 of 1,255

2.2 points

-0.3 to 4.6

2,491NCT02173379

Absorb IV Randomized Controlled Trial

Coronary PCI Guided by OCT vs Coronary PCI Guided by Angiography: deaths from any cause33 of 1,233

44 of 1,254

-0.8 points

-2.2 to 0.5

2,487NCT03507777

ILUMIEN IV: OPTIMAL Percutaneous Coronary Intervention (PCI)

Coronary PCI Guided by OCT vs Coronary PCI Guided by Angiography: serious adverse events405 of 1,233

411 of 1,254

0.1 points

-3.6 to 3.8

2,487NCT03507777

ILUMIEN IV: OPTIMAL Percutaneous Coronary Intervention (PCI)

Fluticasone Maintenance vs Fluticasone Withdrawal: serious adverse events292 of 1,243

300 of 1,242

-0.7 points

-4.0 to 2.7

2,485NCT00975195

Inhaled Corticosteroid Withdrawal in Patients With Chronic Obstructive Pulmonary Disease

Daprodustat vs rhEPO: Number of Hgb Responders in the Hgb Analysis Range (10 to 11.5 Grams/Deciliter) During Evaluation Period (Week 28 to Week 52)903 of 1,238

866 of 1,247

3.5 points

-0.1 to 7.0

2,485NCT02879305

Anemia Studies in Chronic Kidney Disease: Erythropoiesis Via a Novel Prolyl Hydroxylase Inhibitor Daprodustat-Dialysis (ASCEND-D)

ICD Implant Without Defibrillation Testing vs ICD Implant With Defibrillation Testing: Perioperative Complication Rate69 of 1,236

81 of 1,242

-0.9 points

-2.8 to 1.0

2,478NCT00800384

Shockless Implant Evaluation

Treatment vs Control: deaths from any cause134 of 1,245

127 of 1,225

0.4 points

-2.0 to 2.8

2,470NCT02604264

Product Evaluation for the Effectiveness of the ClearGuard™ HD End Cap

Heterosexual and MSM Males vs Females: serious adverse events23 of 1,394

26 of 1,075

-0.8 points

-2.0 to 0.3

2,469NCT01651949

Multivalent HPV (Human Papillomavirus) Vaccine Study in 16- to 26-Year Old Men and Women (V503-003)

Absorb BVS vs XIENCE: Number of Participants With Rehospitalization544 of 1,226

525 of 1,242

2.1 points

-1.8 to 6.0

2,468NCT02173379

Absorb IV Randomized Controlled Trial

Treatment Prevention for Secondary CV vs Cardiovascular Polypill: deaths from any cause117 of 1,229

115 of 1,237

0.2 points

-2.1 to 2.5

2,466NCT02596126

Secondary Prevention of Cardiovascular Disease in the Elderly Trial

Treatment Prevention for Secondary CV vs Cardiovascular Polypill: serious adverse events220 of 1,229

248 of 1,237

-2.1 points

-5.2 to 0.9

2,466NCT02596126

Secondary Prevention of Cardiovascular Disease in the Elderly Trial

Folic Acid 4 mg vs Placebo: serious adverse events227 of 1,227

195 of 1,236

2.7 points

-0.3 to 5.7

2,463NCT01355159

High Dose Folic Acid Supplementation Throughout Pregnancy for Preeclampsia Prevention

Absorb BVS vs XIENCE: Number of Participants Experienced Cardiac Death/TV-MI/ID-TLR (TLF)171 of 1,219

134 of 1,241

3.2 points

0.6 to 5.8

2,460NCT02173379

Absorb IV Randomized Controlled Trial

Absorb BVS vs XIENCE: Number of Participants With Myocardial Infarction (MI)126 of 1,219

104 of 1,241

2.0 points

-0.3 to 4.3

2,460NCT02173379

Absorb IV Randomized Controlled Trial

Request

GET /api/comparisons/v1

Words from a trial's title, conditions or interventions, its outcome or its groups, or an NCT number.

An outcome counted in participants, the serious adverse events, or the deaths from any cause.

No key needed

Code

Show the call in
curl "https://conductscience.org/api/comparisons/v1?page=148"

Response

The first 2 of this page's 20 results. GET /api/comparisons/v1?page=148

{
  "data": {
    "total": 85013,
    "results": [
      {
        "id": "NCT02173379-6c8c8d00",
        "title": "Absorb BVS vs XIENCE: Number of Participants With Target Vessel Revascularization (TVR)",
        "summary": "44 of 1236 against 39 of 1255; risk difference 0.5 points, 95% interval -1.0 to 1.9; NCT02173379, Absorb IV Randomized Controlled Trial",
        "record": "/library/comparisons/NCT02173379-6c8c8d00",
        "nct_id": "NCT02173379",
        "kind": "outcome",
        "participants": 2491,
        "risk_difference": {
          "value": 0.004523008290462746,
          "lower": -0.009768931621627756,
          "upper": 0.018970160745002677
        },
        "group_1": "44 of 1,236",
        "group_2": "39 of 1,255",
        "difference": "0.5 points",
        "interval": "-1.0 to 1.9",
        "trial_title": "Absorb IV Randomized Controlled Trial"
      },
      {
        "id": "NCT02173379-780d0b2a",
        "title": "Absorb BVS vs XIENCE: Number of Participants Experienced All Death/All MI",
        "summary": "116 of 1236 against 106 of 1255; risk difference 0.9 points, 95% interval -1.3 to 3.2; NCT02173379, Absorb IV Randomized Controlled Trial",
        "record": "/library/comparisons/NCT02173379-780d0b2a",
        "nct_id": "NCT02173379",
        "kind": "outcome",
        "participants": 2491,
        "risk_difference": {
          "value": 0.009388981291661824,
          "lower": -0.013060164339266024,
          "upper": 0.03192196220472632
        },
        "group_1": "116 of 1,236",
        "group_2": "106 of 1,255",
        "difference": "0.9 points",
        "interval": "-1.3 to 3.2",
        "trial_title": "Absorb IV Randomized Controlled Trial"
      }
    ],
    "no_events": 33758,
    "columns": [
      {
        "key": "title",
        "label": "Comparison"
      },
      {
        "key": "group_1",
        "label": "With the outcome",
        "under": "group_2"
      },
      {
        "key": "difference",
        "label": "Risk difference, 95% interval",
        "under": "interval"
      },
      {
        "key": "participants",
        "label": "Participants"
      },
      {
        "key": "nct_id",
        "label": "Trial",
        "under": "trial_title"
      }
    ],
    "order": "Most participants first",
    "kinds": {
      "all": 85013,
      "outcome": 33568,
      "serious-adverse-events": 31897,
      "deaths": 19548
    }
  },
  "release": "trial-comparisons-2026-03-23-0.1.0",
  "terms": [
    {
      "source": "ClinicalTrials.gov's posted results, through CTTI's AACT",
      "license": "ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299",
      "notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
      "short": "Freely available. Acknowledgement requested"
    },
    {
      "source": "ClinicalTrials.gov",
      "license": "none stated",
      "notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
      "short": "No license stated"
    }
  ],
  "next": "/api/comparisons/v1?page=149",
  "request_id": "19jEGEPAa6MTOWIN"
}

Ask about these results. The first 10 go in the prompt.

About this data
Holds
85,013 comparisons
From ClinicalTrials.gov. Counted 10 Nov 2026.
Release
23 Mar 2026
trial-comparisons-2026-03-23-0.1.0
Checked
20 of 20 review comparisons traced to ClinicalTrials.gov, and all 510,078 numbers calculated again apart from the builder agree
Access
Open
No account. 60 calls a minute from one address.

Sources 2

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.

Genes

NCBI Gene

One gene with its proteins, patents, drugs, trials, grants and papers.

Trials

ClinicalTrials.gov

Search clinical trials by condition, drug, outcome or NCT number, with the results each one posted.

Sequences

Patent publications

Paste a sequence and see the patents that disclose it.

Opens sequences.conductscience.org

For software

Read Trial comparisons from software.

Every answer on this page is also JSON, under /api/comparisons/v1. No key.

GET https://conductscience.org/api/comparisons/v1?q=placebo%20heart%20failure&kind=outcome

Ask an assistant

  • In FOURIER, how did serious adverse events compare between evolocumab and placebo?
  • Which metformin trials reported deaths, and what was the risk difference?
  • What was the number needed to treat for HELIOS-B's composite outcome?
  • Which placebo-controlled heart failure trials had the most participants?